Seven, believe this is small potatoes in comparison with the sunk costs for the 2700 patient P3 which Biogen is conducting with Aducanumab. These huge trials conducted in over 200 locations in a number of countries have a tremendous level of momentum and I'm afraid Vounatsos has little control of this because they were approved by Biogen's BOD before he came onboard. These two trials will not read out before 2019/2020.
If ANAVEX 2-73 proves effective in the next year and 3-71 has an even brighter future in AD, IMHO Biogen will turn around midstream and make a play of some magnitude for 2-73. This will be especially true if they partner with us for M/S
There is more of a likelihood of BIIB being interested in the MS application for 2-73 than AD.
I don’t think BIIB is going to make an offer for AVXL. I would be very happy to be wrong about that. And I certainly wouldn’t be shocked if it happened.
Better to not set your sights too high and risk disappointment. For right now, looking forward to guaranteed positive catalysts for the rest of the year.
News 
Market Data 
Discover 
